IVDR Webinar

IVDR Economic Operator

View on-demand webinar

View on-demand webinar

Requirements to economic operators

In this webinar series, our expert discuss the requirements to economic operators introduced by the European In Vitro Regulation EU 2017/746.Economic operators in the context of the regulation include manufacturers, authorized representatives, importers, and distributors.

In this webinar, we will be discussing the requirement for each of those operators but also the responsibilities toward each other.
The expert will also cover the increasing responsibilities and liabilities taken by authorized representative in the compliance of the product, the new reporting and controlling activities assigned to importers and distributors.

The role of all economic operators will change with the new regulation and this webinar will help the manufacturer to identify the new relationship to build with each of them and smoothly prepare the transition to EU IVDR. By May 26, 2022, the In Vitro Diagnostic Regulation will be applied to all devices sold in the European Union.

This episode is the third part of a series of webinars. Watch all the episodes here:
IVDR EU 2017/746 Overview - Part 1
IVDR Performance Evaluation and Post Market - Part 2
IVDR Classification Rules - Part 4

Complete the form to view the on-demand webinar!

About the speaker

Dr. Julien SenacDr. Julien Senac

Global Director of IVD Focus Team, TÜV SÜD

Dr. Julien Senac is currently Global Director of the IVD Focus Team at TÜV SÜD. Before this, he has many years of experience with a certification body, where he participated in the preparation of IVDR designation and performed Design Dossier assessment of in vitro diagnostic devices. Dr. Senac has a Ph.D. in Molecular and Human Genetics from Baylor College of Medicine (Houston, TX) and more than 10 years of experience in biomedical research. He worked in top research/medical institutions in the United States such as Mayo Clinic and the National Institutes of Health. Dr. Senac has also participated in the development of multiple biotech start-up companies in oncology, gene therapy, and AIDs technologies.

Next Steps

Site Selector